Sue Friedman on Informed Decision-Making in Hereditary Cancers

Patients with triple-negative breast cancer with an increased TIL count in breast tissue were more likely to have an improved distant recurrence-free survival.

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Trastuzumab deruxtecan enhanced survival without disease progression compared with chemotherapy in HR-positive, HER2-low metastatic breast cancer after 1 or more lines of endocrine therapy.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

From journaling to delegating everyday tasks, nurses can teach patients how to cope with treatment-related fatigue.

Trastuzumab-strf was approved for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma.